Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer
Key Points
Treatment progression varies significantly based on homologous recombination repair mutations and race, indicating potential disparities.
Key evidence shows 20% of patients had HRR mutations, and those mutations were linked to treatment responses.
Analysis explored next-generation sequencing data to assess the impact of genetic mutations on treatment outcomes.
Highlighting the need for tailored approaches in managing prostate cancer treatment, especially in racially diverse populations.
Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer | Synapse